Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&D expenses up 35.5% to USD 48.94 million

Reuters03-18

Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&D expenses up 35.5% to USD 48.94 million

Gossamer published a fourth-quarter and full-year 2025 earnings press release, reporting a Q4 net loss of USD 47.24 million, or USD 0.21 per share. Q4 R&D expenses rose 35.5% to USD 48.94 million, while G&A expenses increased 16.1% to USD 10.9 million. For FY 2025, net loss widened to USD 170.37 million, compared with FY 2024. FY 2025 R&D expenses increased 25.7% to USD 174.09 million, and cash, cash equivalents and marketable securities fell 53.5% to USD 136.93 million at year-end. Management said it is evaluating the PROSERA Phase 3 dataset, plans to request a Type C FDA meeting potentially in June 2026, and has paused enrollment in the SERANATA Phase 3 PH-ILD study while assessing implications of the PROSERA results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603171601BIZWIRE_USPR_____20260317_BW488156) on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620040833?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 04:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620040833","market":"fut","top_or_hot":-1,"title":"Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&D expenses up 35.5% to USD 48.94 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&amp;D expenses up 35.5% to USD 48.94 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gossamer published a fourth-quarter and full-year 2025 earnings press release, reporting a Q4 net loss of USD 47.24 million, or USD 0.21 per share. Q4 R&amp;D expenses rose 35.5% to USD 48.94 million, while G&amp;A expenses increased 16.1% to USD 10.9 million. For FY 2025, net loss widened to USD 170.37 million, compared with FY 2024. FY 2025 R&amp;D expenses increased 25.7% to USD 174.09 million, and cash, cash equivalents and marketable securities fell 53.5% to USD 136.93 million at year-end. Management said it is evaluating the PROSERA Phase 3 dataset, plans to request a Type C FDA meeting potentially in June 2026, and has paused enrollment in the SERANATA Phase 3 PH-ILD study while assessing implications of the PROSERA results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GOSS\">Gossamer Bio Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 202603171601BIZWIRE_USPR_____20260317_BW488156) on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&D expenses up 35.5% to USD 48.94 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&D expenses up 35.5% to USD 48.94 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 04:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&amp;D expenses up 35.5% to USD 48.94 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gossamer published a fourth-quarter and full-year 2025 earnings press release, reporting a Q4 net loss of USD 47.24 million, or USD 0.21 per share. Q4 R&amp;D expenses rose 35.5% to USD 48.94 million, while G&amp;A expenses increased 16.1% to USD 10.9 million. For FY 2025, net loss widened to USD 170.37 million, compared with FY 2024. FY 2025 R&amp;D expenses increased 25.7% to USD 174.09 million, and cash, cash equivalents and marketable securities fell 53.5% to USD 136.93 million at year-end. Management said it is evaluating the PROSERA Phase 3 dataset, plans to request a Type C FDA meeting potentially in June 2026, and has paused enrollment in the SERANATA Phase 3 PH-ILD study while assessing implications of the PROSERA results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GOSS\">Gossamer Bio Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 202603171601BIZWIRE_USPR_____20260317_BW488156) on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4TCG92:1","article_id":"2620040833","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620040833","pubTimestamp":1773777795,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Gossamer published a fourth-quarter and full-year 2025 earnings press release, reporting a Q4 net loss of USD 47.24 million, or USD 0.21 per share. Q4 R&D expenses rose 35.5% to USD 48.94 million, while G&A expenses increased 16.1% to USD 10.9 million. For FY 2025, net loss widened to USD 170.37 million, compared with FY 2024. FY 2025 R&D expenses increased 25.7% to USD 174.09 million, and cash, cash equivalents and marketable securities fell 53.5% to USD 136.93 million at year-end. Management said it is evaluating the PROSERA Phase 3 dataset, plans to request a Type C FDA meeting potentially in June 2026, and has paused enrollment in the SERANATA Phase 3 PH-ILD study while assessing implications of the PROSERA results.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","GOSS":"Gossamer Bio Inc."},"translate_title":"Gossamer Bio第四季度净亏损上升43.01%至4724万美元，研发费用上升35.5%至4894万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GOSS":0.9},"content_text":"Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&D expenses up 35.5% to USD 48.94 million\n    \n\n        Gossamer published a fourth-quarter and full-year 2025 earnings press release, reporting a Q4 net loss of USD 47.24 million, or USD 0.21 per share. Q4 R&D expenses rose 35.5% to USD 48.94 million, while G&A expenses increased 16.1% to USD 10.9 million. For FY 2025, net loss widened to USD 170.37 million, compared with FY 2024. FY 2025 R&D expenses increased 25.7% to USD 174.09 million, and cash, cash equivalents and marketable securities fell 53.5% to USD 136.93 million at year-end. Management said it is evaluating the PROSERA Phase 3 dataset, plans to request a Type C FDA meeting potentially in June 2026, and has paused enrollment in the SERANATA Phase 3 PH-ILD study while assessing implications of the PROSERA results.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603171601BIZWIRE_USPR_____20260317_BW488156) on March 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620040833","isCrawlerRequest":true}